The experience of disproportionate supplies of COVID-19 vaccines to Africa: the need for Africa to decolonize its public health response

The recent outbreak of COVID-19 resulted in high fatality rates globally and huge socio-economic consequences. Vaccine development was considered as the most effective and fastest means to reduce the risks associated with the disease. All hands were on deck for effective vaccine development which resulted in several countries including African countries participating in the vaccine solidarity trial. At the heat of the pandemic in 2021, Africa with a population of 1.4 billion had 134.5 million supplies of COVID-19 vaccines. The United States in contrast with a population of 332 million had over 375 million doses of the vaccine. This was one of the factors that hindered most African countries from meeting up with the World Health Organization (WHO) target of 40% fully vaccinated individuals by December 2021. Even in some African countries where there were early and good supplies, there was vaccine wastage due to near to expire vaccines supplied to such countries which resulted in misconception and rejection of the vaccines among the public. This paper discussed the politics of COVID-19 vaccine production and distribution with its effects on Africa using documentary analysis. The paper also suggests strategic bold steps needed to be taken by African countries to decolonize public health response within the continent in preparation for future pandemics.